The purpose of this study is to evaluate the efficacy, safety, and tolerability of the medication MK-5475 in participants with Pulmonary Arterial Hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH). MK-5475 will be administered through a dry powder inhaler system that is designed to be taken once daily in the mornings. The duration of this study is 12 weeks, with the option for extension for patients participating in phase 3 of this study.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Jimmy Ford
Medicine-Pulmonary
Clinical or Medical
Interventional
Heart and Circulation
Lungs and Breathing
Rare Diseases
21-0053
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
